NCT01662986 - Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2012

Primary Completion Date

April 1, 2014

Study Completion Date

April 1, 2014

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

tiotropium bromide

18 mcg once a day (QD)

DRUG

Placebo

Once a day (QD)

Trial Locations (50)

Unknown

205.478.00243 Boehringer Ingelheim Investigational Site, Montgomery

205.478.00208 Boehringer Ingelheim Investigational Site, Flagstaff

205.478.00260 Boehringer Ingelheim Investigational Site, Glendale

205.478.00241 Boehringer Ingelheim Investigational Site, Loma Linda

205.478.00240 Boehringer Ingelheim Investigational Site, Long Beach

205.478.00237 Boehringer Ingelheim Investigational Site, Torrance

205.478.00231 Boehringer Ingelheim Investigational Site, Denver

205.478.00209 Boehringer Ingelheim Investigational Site, Danbury

205.478.00250 Boehringer Ingelheim Investigational Site, Glastonbury

205.478.00229 Boehringer Ingelheim Investigational Site, Hartford

205.478.00200 Boehringer Ingelheim Investigational Site, Jacksonville

205.478.00212 Boehringer Ingelheim Investigational Site, Jacksonville

205.478.00265 Boehringer Ingelheim Investigational Site, Kissimmee

205.478.00246 Boehringer Ingelheim Investigational Site, Lehigh Acres

205.478.00248 Boehringer Ingelheim Investigational Site, Miami

205.478.00215 Boehringer Ingelheim Investigational Site, Orlando

205.478.00261 Boehringer Ingelheim Investigational Site, St. Petersburg

205.478.00233 Boehringer Ingelheim Investigational Site, Vero Beach

205.478.00236 Boehringer Ingelheim Investigational Site, Austell

205.478.00205 Boehringer Ingelheim Investigational Site, Lawrenceville

205.478.00225 Boehringer Ingelheim Investigational Site, Evanston

205.478.00264 Boehringer Ingelheim Investigational Site, Iowa City

205.478.00254 Boehringer Ingelheim Investigational Site, Olathe

205.478.00249 Boehringer Ingelheim Investigational Site, Topeka

205.478.00257 Boehringer Ingelheim Investigational Site, Hazard

205.478.00234 Boehringer Ingelheim Investigational Site, Lexington

205.478.00242 Boehringer Ingelheim Investigational Site, Louisville

205.478.00258 Boehringer Ingelheim Investigational Site, Eunice

205.478.00256 Boehringer Ingelheim Investigational Site, New Orleans

205.478.00210 Boehringer Ingelheim Investigational Site, Baltimore

205.478.00220 Boehringer Ingelheim Investigational Site, Towson

205.478.00204 Boehringer Ingelheim Investigational Site, North Dartmouth

205.478.00247 Boehringer Ingelheim Investigational Site, Winston Salem

205.478.00263 Boehringer Ingelheim Investigational Site, Rochester

205.478.00201 Boehringer Ingelheim Investigational Site, Chesterfield

205.478.00239 Boehringer Ingelheim Investigational Site, Kansas City

205.478.00227 Boehringer Ingelheim Investigational Site, Summit

205.478.00253 Boehringer Ingelheim Investigational Site, The Bronx

205.478.00226 Boehringer Ingelheim Investigational Site, Chapel Hill

205.478.00232 Boehringer Ingelheim Investigational Site, Cleveland

205.478.00203 Boehringer Ingelheim Investigational Site, Philadelphia

205.478.00206 Boehringer Ingelheim Investigational Site, Wyomissing

205.478.00219 Boehringer Ingelheim Investigational Site, Easley

205.478.00222 Boehringer Ingelheim Investigational Site, Arlington

205.478.00235 Boehringer Ingelheim Investigational Site, Kingwood

205.478.00217 Boehringer Ingelheim Investigational Site, McKinney

205.478.00216 Boehringer Ingelheim Investigational Site, Temple

205.478.00230 Boehringer Ingelheim Investigational Site, Falls Church

205.478.00202 Boehringer Ingelheim Investigational Site, Richmond

205.478.00224 Boehringer Ingelheim Investigational Site, Tacoma